Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Minocycline Stories

2010-03-23 11:55:00

CLEVELAND, March 23 /PRNewswire/ -- Magellan Biosciences, Inc., an emerging leader in clinical diagnostics products, announced that the company has become the first to offer minocycline and telavancin on IVD-labeled microbroth dilution susceptibility plates. The U.S. Food and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC plates for testing minocycline against Gram positive and Gram negative bacterial isolates, as well as telavancin against Gram positive bacterial isolates...

73c07dd1b5250250ca9934550a1530de1
2010-03-20 13:30:00

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating. The drug, minocycline, likely will improve on the current treatment regimens of HIV-infected patients if used in combination with a standard drug cocktail known as HAART (Highly Active Antiretroviral Therapy), according to research...

2009-12-08 09:00:00

WALNUT CREEK, Calif., Dec. 8 /PRNewswire/ -- The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment. The two-year study will evaluate the efficacy of...

2009-10-06 10:25:54

The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models. Dr. Cesar V. Borlongan from the University of South Florida, USA worked with a team of researchers to test the treatment in laboratory experiments. He said, "To date, the thrombolytic agent tPA is the only effective drug for acute ischemic stroke; however, only about 2% of ischemic...

2008-11-11 09:00:47

SCOTTSDALE, Ariz., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the Company is scheduled to present at the 2008 Credit Suisse Healthcare Conference in Phoenix, Arizona. A live webcast of its presentation scheduled for Thursday, November 13, 2008, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time), may be accessed via the Internet. The webcast will be available via a link on the Medicis corporate website at http://www.Medicis.com/company/index.asp. This link...

2008-11-06 09:00:45

SCOTTSDALE, Ariz., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced it expects to report 2008 third quarter financial results after the market closes on Monday, November 10, 2008. Medicis will host a conference call at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) to review the September 30, 2008, third quarter financial results, as well as provide an update on other business matters of the Company. A live webcast will be available at...

2008-10-10 09:00:19

SCOTTSDALE, Ariz., Oct. 10, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced the U.S. Food and Drug Administration (FDA) has approved its premarket approval application (PMA) supplement, based on clinical data which highlights RESTYLANE(R)'s duration effect up to 18 months in 97% of patients with repeated treatment. The RESTYLANE(R) package insert will be amended to include the study results. The Company anticipates using this information in its promotional activities. About the...

2008-09-17 09:01:00

SCOTTSDALE, Ariz., Sept. 17, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that its Board of Directors declared a quarter-end cash dividend of $0.04 per issued and outstanding share of its Common Stock payable on October 31, 2008, to stockholders of record at the close of business on October 1, 2008. About Medicis Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic...

2008-09-05 15:00:31

DEAR DR. DONOHUE: I am a 15-year-old girl with less-than-perfect skin. My back, chest and face break out constantly. My mom suggested taking birth control pills, but I am hesitant. Fifteen seems too early. My mom was recently hospitalized for a blood clot, and the doctors said it could have been caused by the birth control pill. I currently am taking minocycline, but it doesn't always work. What should I do? - H.F. ANSWER: Fighting acne involves conducting warfare on many fronts. One front...

2008-09-02 09:00:43

SCOTTSDALE, Ariz., Sept. 2, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the Company is scheduled to present at the Thomas Weisel Partners Healthcare Conference 2008 in Boston, Massachusetts. A live webcast of its presentation scheduled for Thursday, September 4, 2008, at 2:05 p.m. Eastern Time (11:05 a.m. Pacific Time), may be accessed via the Internet. The webcast will be available via a link on the Medicis corporate website at http://www.medicis.com/company/index.asp....